About US
Contact us
-
On heels of Loxo buy, Lartruvo setback deals a blow to Lilly's oncology hopesAfter patent expirations and other woes,Eli Lilly has been leaning on a stable of new drugs for growth. But aftera trial failure for soft tissue sarcoma launch Lartruvo, the drugmaker is stopping prom2019/1/22
-
Sun Pharma drops to 6-year low on report of another whistleblower complaintJust weeks after Sun Pharma’s stock was hit by whistleblower allegations of insider trading, a second complaint reportedly filed to Indian regulators sent the drugmaker’s shares tumbling to a new six-2019/1/21
-
Lilly price break reverses NICE’s 'No' ruling on breast cancer drug VerzenioLast October, England’s drug-cost watchdogs dealt Eli Lilly a blow when they decreedthat the company’s CDK 4/6 inhibitor to treat breast cancer, Verzenio, wasn'tcost-effective. So Lilly dished up a ne2019/1/21
-
AstraZeneca licences Luye Pharma cholesterol drug in ChinaLuye Pharma has granted AstraZeneca’s Chinese division exclusive rights to promote its cholesterol medicine Xuezhikang Capsules in mainland China. The drug, made by fermenting red yeast rice, is indi2019/1/18
-
FDA announces new policies for cell and gene therapiesDespite most of the US Food and Drug Administration’s (FDA) responsibilities grinding to a halt as a result of the US Government shut down, FDA commissioner Scott Gottlieb and Centre for Biologics Eva2019/1/18
-
US Oversight Committee launches drug price probe into major companiesThe US Committee on Oversight and Reform chairman Elijah Cummings has launched an investigation into the drug pricing practices of multiple pharmaceutical companies. The move comes less than a week a2019/1/17
-
Eisai and Purdue Pharma seek US approval for lemborexant to treat insomniaEisai and its partner Purdue Pharma have submitted new drug application to the US Food and Drug Administration (FDA) seeking approval for lemborexant to treat insomnia, a sleep disorder. Lemborexant2019/1/17
-
European and UK pharma industry call for action as parliament rejects Brexit dealThe European and UK pharma industry have called for preparations to ensure that patients will have access to their medications in case of a no-deal Brexit by 30 March 2019. The call follows parliamen2019/1/16
-
Teva secures US regulatory approval for generic version of SabrilTeva Pharmaceuticals USA has secured approval from the US Food and Drug Administration (FDA) for its generic version of Sabril (vigabatrin) drug to treat complex partial seizures, otherwise known as f2019/1/16
-
First its CEO tells pharma to watch it on pricing—and then Johnson & Johnson raises themCall it dramatic irony. Speaking to his biopharma colleagues this week in San Francisco, Johnson & Johnson CEO Alex Gorsky said the pharma industry needs to watch itself on pricing, but only days2019/1/15